Dermatology practical & conceptual最新文献

{"title":"Reflectance Confocal Microscopy of Sweet Syndrome.","authors":"François Skowron, Amélie Carbonnelle-Puscian, Marco Ardigò","doi":"10.5826/dpc.1501a4929","DOIUrl":"10.5826/dpc.1501a4929","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study.","authors":"Ece Erbağcı, Özge Sevil Karstarlı Bakay, Fatma Aslı Hapa","doi":"10.5826/dpc.1501a4915","DOIUrl":"10.5826/dpc.1501a4915","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the effectiveness and safety of secukinumab (SEC) in the treatment of HS have been demonstrated in phase III studies, real-world data is limited.</p><p><strong>Objectives: </strong>We conducted a retrospective multicenter study to evaluate the effectiveness and safety of SEC treatment in HS patients in real-world settings.</p><p><strong>Methods: </strong>Adult patients who were diagnosed with HS and used SEC for at least 3 months were included in the study.</p><p><strong>Results: </strong>A total of 31 patients were included in the study; 14 of them (45.2%) were female. The mean age was 39.32 ± 10.26 years, and the mean disease duration was 11.77 ± 7.99 years. Nine (29%) patients were biologic-naive and 10 (32.3%) were adalimumab-naive. Disease severity was Hurley I in 7 patients (22.6%), Hurley II in 9 patients (29%), and Hurley III in 15 patients (48.4%). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 20 patients (64.5%) in the third month of treatment. SEC treatment was discontinued due to primary ineffectiveness in 9 (29%) patients, secondary ineffectiveness in 1 (3.2%) patient, adverse effects in 1 (3.2%) patient, and loss of follow-up in 1 (3.2%) patient. Paradoxical pyoderma gangrenosum was observed as an adverse effect in 1 patient that resolved after discontinuing SEC and starting infliximab.</p><p><strong>Conclusions: </strong>SEC appears to be an effective and safe treatment option for HS, especially when used in the early and mild stages of the disease and in biologic-naive patients.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender-related Therapeutical Response to Apremilast: New Insights in a Tailored Management of Psoriasis.","authors":"Emanuele Trovato, Federico Bardazzi, Vito Di Lernia, Monica Corazza, Claudia Lasagni, Francesca Prignano","doi":"10.5826/dpc.1501a4805","DOIUrl":"10.5826/dpc.1501a4805","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated skin condition. One of the intriguing challenges in studying psoriasis has been identification of correlations between this disease and gender and body weight.</p><p><strong>Objectives: </strong>A multicenter retrospective study was conducted among patients with moderate-to-severe psoriasis who attended the outpatient clinics of 6 University Hospitals in Italy. The effects of apremilast on weight and body mass index (BMI) according to gender after 24 weeks and 48 weeks of therapy were considered.</p><p><strong>Methods: </strong>We enrolled retrospectively 120 adult patients with moderate-to-severe psoriasis who underwent apremilast treatment for at least 24 weeks. Baseline characteristics, including age, gender, psoriasis area severity index (PASI), comorbidities, smoking and alcohol habits, relevant medical history and previous psoriasis systemic and biologic treatments were recorded. Weight and BMI were evaluated at baseline (T0) and at 24 (w24) and 48 weeks (w48). A descriptive statistical analysis has been performed.</p><p><strong>Results: </strong>The analysis showed a significant reduction in body weight in females at w24 and w48 (P < 0.001), with a mean difference of -2.6 kg at w24 and of -5.7 kg at w48. We observed a reduction of weight of 3.6% at w24, and 7.9% at w48. Similar assessments were also observed for BMI, which was reduced in women by 3.6% at w24 and 8% at w48. In men, no changes in weight and BMI were observed at w24 and/or w48.</p><p><strong>Conclusions: </strong>Understanding the interplay between psoriasis, gender, and body weight is essential for effective disease management and improving patient outcomes.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Anemia and Telogen Effluvium in Post-COVID-19 Survivors.","authors":"Canan Emiroglu, Murat Dicle, Süleyman Görpelioglu, Cenk Aypak","doi":"10.5826/dpc.1501a4234","DOIUrl":"10.5826/dpc.1501a4234","url":null,"abstract":"<p><strong>Introduction: </strong>There are insufficient studies in the literature on the relationship between the acute severity of disease and the occurrence of anemia and telogen effluvium (TE) in the post-coronavirus disease 2019 (COVID-19) period.</p><p><strong>Objectives: </strong>The purpose of this study was to investigate the relationship between anemia and TE in individuals who had experienced COVID-19 during the post-COVID period.</p><p><strong>Method: </strong>The study has a retrospective cross-sectional design and was conducted on patients presenting to a tertiary care hospital for COVID-19 follow-up. Patient data, including demographic parameters, data regarding smoking history, comorbidities, symptoms, and laboratory panel at presentation, were evaluated.</p><p><strong>Results: </strong>Out of 672 patients, 249 had TE complaints. TE was more common in females, those under the average age of this patient group, and those with a body mass index of under 25. Anemia was identified in 80 patients. Among individuals with anemia, TE was observed in 47.3%, whereas among those without anemia, the occurrence of TE was noted at a rate of 35.5%. When the severity of infection in the acute phase was examined in relation to the presence of TE in the post-COVID period, TE was observed in 45.1% of those receiving outpatient treatment, 37.0% of those hospitalized, and 30.7% of those in intensive care.</p><p><strong>Conclusion: </strong>The results obtained in this study group indicate that TE complaints after COVID-19 are more common in those with anemia, but the fact that they did not correlate with the acute disease's severity requires consideration of other causes besides the virus effect.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Accuracy of Dermoscopy for Scabies Diagnosis in Dark African Skin.","authors":"Nkechi Anne Enechukwu, Ikenna Akuakolam, Iloduba Nnaemeka Aghanya, Chetanna Chioma Anaje, Ogochukwu Ifeanyi Ezejiofor, Enzo Errichetti","doi":"10.5826/dpc.1501a4848","DOIUrl":"10.5826/dpc.1501a4848","url":null,"abstract":"<p><strong>Introduction: </strong>Scabies, a parasitic infestation caused by Sarcoptes scabiei var hominis, affects individuals of diverse skin types. While definitive diagnosis involves identifying adult mites, eggs, or scybala from the microscopy of scrapings obtained from representative sites, it is invasive, time-consuming, and not feasible in very young or non-cooperative patients. Dermoscopy is an evolving non-invasive procedure useful in dermatological diagnosis. The handheld dermatoscope is portable and valuable for epidemics and in vivo use. There are sparse data on the diagnostic accuracy of dermoscopy versus microscopy in darker skin phototypes, a demographic for which dermoscopy have been understudied.</p><p><strong>Objective: </strong>This study aimed to compare the diagnostic accuracy of dermoscopy with microscopy in dark skin.</p><p><strong>Methods: </strong>Consecutive patients attending the dermatology clinic at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, with clinical suspicion of scabies underwent dermoscopic and microscopic examination. Definitive diagnosis was retrospective, and a comparative assessment between dermoscopy and microscopy was conducted.</p><p><strong>Results: </strong>Dermoscopic and microscopic evidence was observed in 48.3% and 46.7%, respectively. While the serpiginous tract had a sensitivity and specificity of 75.9% and 80.6%, respectively, delta sign was 75% and 55.4%, respectively. Both dermoscopy and microscopy demonstrated a sensitivity and specificity of 75% and 55.4%, respectively. The delta glider sign was seen in four participants.</p><p><strong>Conclusion: </strong>Dermoscopy is particularly effective in identifying the serpiginous tract of scabies on dark skin, although it is less effective for detecting the delta sign. Non-specific dermoscopic features may frequently be seen. Future studies should modify criteria for darker skin to enhance clinical accuracy.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab.","authors":"Efterpi Zafiriou, Emmanouil Karampinis, Vasileios Papadopoulos, Georgia Stefani, Athanasios Kotsakis, George Vassilopoulos","doi":"10.5826/dpc.1501a4642","DOIUrl":"10.5826/dpc.1501a4642","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Chagas Disease (American Trypanosomiasis).","authors":"Alejandro Marcel Hasslocher-Moreno, André Luiz Land Curi, Maria Clara Gutierrez Galhardo","doi":"10.5826/dpc.1501a4770","DOIUrl":"10.5826/dpc.1501a4770","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vivo Characterization of the Inflammatory Infiltrate in Discoid Lupus Erythematosus (DLE) by Line-Field Confocal Optical Coherence Tomography (LC-OCT).","authors":"Pierfrancesco Benvenuto, Vittorio Tancredi, Andrea Ronchi, Camila Scharf, Elisabetta Fulgione, Elvira Moscarella","doi":"10.5826/dpc.1501a5089","DOIUrl":"10.5826/dpc.1501a5089","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.","authors":"Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone","doi":"10.5826/dpc.1501a4838","DOIUrl":"10.5826/dpc.1501a4838","url":null,"abstract":"<p><strong>Introduction: </strong>Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis.</p><p><strong>Objectives: </strong>We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting.</p><p><strong>Methods: </strong>A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator.</p><p><strong>Results: </strong>Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 (79.7% versus 64.2% (P = 0.041) and 98.6% versus 83.6% (P = 0.003), respectively). Risankizumab also showed superior PASI100 rates at week 52 (85.5% versus 65.6%, P = 0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively).</p><p><strong>Conclusions: </strong>Risankizumab showed superior efficacy than secukinumab and a lower cost per responder.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propranolol: A Promising Therapeutic Avenue for Classic Kaposi Sarcoma.","authors":"Rasha Mahmoud Genedy, Marwa Owais, Naglaa Mohamed El Sayed","doi":"10.5826/dpc.1501a4737","DOIUrl":"10.5826/dpc.1501a4737","url":null,"abstract":"<p><strong>Introduction: </strong>Kaposi sarcoma (KS) is a low grade angio-proliferative tumor of endothelial origin. Human herpesvirus 8 (HHV8) plays a major role in the pathogenesis of KS. Classic Kaposi sarcoma is commonly seen among elderly of Mediterranean origin. It is usually slowly progressive and is rarely fatal. There is no definitive cure for KS. Beta blockers were used with great success in the treatment of infantile hemangioma. Because of some similarity between infantile hemangioma and KS, topical beta blockers were tried with variable success rate.</p><p><strong>Objectives: </strong>We aimed to assess the efficacy and safety of oral propranolol in the treatment of classic KS.</p><p><strong>Methods: </strong>Fifteen patients diagnosed with classic KS were prospectively enrolled in the study. Detailed history and full clinical examination were conducted. Histopathological diagnosis with confirmatory immune staining was done for all patients. Oral propranolol in a dose of 60 mg was given per day for 6 months. The patients assessed clinically as complete responders, partial responders, and non-responders.</p><p><strong>Results: </strong>Nine patients (60%) were partial responders; showed 50% reduction in the number of the existing lesions, and 6 patients (40%) were considered non-responders; 3 with stable disease and 3 with progressive disease. Lymphedema partially improved in 1 patient.</p><p><strong>Conclusions: </strong>Oral propranolol is a safe and good option for treatment of patients with non-complicated classic KS, especially elderly with multiple comorbidities.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}